CRC_CLEE011A2404

COMPLEEMENT An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease

The purpose of this Phase IIIb study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and postmenopausal women with HR+HER2- advanced breast cancer.

Key Inclusion Criteria:
Hormone-Positive, HER2-Negative, metastatic breast cancer
Men and post-menopausal women
Able to swallow tablets
Phase III
NCT02941926
Cancer
Breast
Peter Jiang, M.D., Ph.D.
Novartis
Rachel Macomber
  • Providence Regional Cancer Partnership - Everett